Will World's Largest HCV Population Have Access To Newest Treatments?
This article was originally published in PharmAsia News
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources
You may also be interested in...
Roche Pharmaceuticals Asia Pacific Head Luke Miels talks to PharmAsia News about the company’s recent deal with Ascletis, its thinking on China’s hepatitis C market and additional opportunities for out-licensing.
BMS’ hepatitis B therapy Baraclude moves toward blockbuster status as company highlights risk of drug resistance with older treatments.
Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations
TOKYO - Telaprevir and a metastatic breast cancer indication for Avastin (bevacizumab) were among the blanket recommendations for approval by the Second Subcommittee on New Drugs of Japan's Ministry of Health, Labor and Welfare announced late in the day Aug. 25. Avastin's recommendation came just a few weeks after the subcommittee had expressed doubts about the drug's efficacy